The visibility of Mach7 Technologies' products and its standing for future contracts should be increased, according to Morgans, following a "monster" contact win with the US Department of Veterans Affairs.

The $60m total contact value (TCV) over the next eight years rectifies prior investor concerns around lumpiness of cashflows and dearth of progress in tier-one contracts, explains the analyst.

Even after a strong post-announcement share price rally, the broker eyes a strong buying opportunity. The target rises to $1.67 from $1.34. Add.

Sector: Health Care Equipment & Services.

Target price is $1.67.Current Price is $0.62. Difference: $1.05 - (brackets indicate current price is over target). If M7T meets the Morgans target it will return approximately 63% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2023 Acquisdata Pty Ltd., source FN Arena